North America’s medical devices industry saw a drop of 7.48% in deal activity during January 2022

North America’s medical devices industry saw a drop of 7.48% in deal activity during January 2022, when compared with the last 12-month average, led by Owens & Minor’s $1.6bn acquisition of Apria, according to GlobalData’s deals database.

 

A total of 99 medical devices industry deals worth $4.7bn were announced for the region in January 2022, against the 12-month average of 107 deals.

Of all the deal types, venture financing saw most activity in January 2022 with 57 transactions, representing a 57.6% share for the region.

In second place was M&A with 33 deals, followed by private equity deals with nine transactions, respectively capturing a 33.3% and 9.1% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $3.27bn, while venture financing and private equity deals totalled $1.17bn and $250m, respectively.

North America medical devices industry deals in January 2022: Top deals

The top five medical devices deals accounted for 67.4% of the overall value during January 2022.

The combined value of the top five medical devices deals stood at $3.16bn, against the overall value of $4.7bn recorded for the month.

The top five medical devices industry deals of January 2022 tracked by GlobalData were:

1) Owens & Minor $1.6bn acquisition deal with Apria

2) The $623m acquisition of GeneDX by Sema4 OpCo

3) ConvaTec Group $450m acquisition deal with Triad Life Sciences

4) The $250m private equity of Fluidigm by Casdin Capital and Viking Global Investors

5) Maravai LifeSciences Holdings $240m acquisition deal with MyChem